menu
    • menu
    [{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Series B Financing","leadProduct":"AUTX-703","moa":"KAT2A\/B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ DCVC Bio","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ DCVC Bio"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"DCVC Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ DCVC Bio","highestDevelopmentStatusID":"2","companyTruncated":"Auron Therapeutics \/ DCVC Bio"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AUTX-703","moa":"KAT2A\/B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"AUTX-703","moa":"KAT2A\/B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Auron Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"AUTX-703","moa":"KAT2A\/B","graph1":"Oncology","graph2":"IND Enabling","graph3":"Auron Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Auron Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Auron Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Auron Therapeutics

    Menu

    Auron Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Auron Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Auron Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUTX-703

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Auron Announces AUTX-703 Granted Fast Track Designation by the FDA for R/R AML

                            Details : AUTX-703 is a novel, first-in-class, oral KAT2A/B degrader, which is being evaluated for the treatment of relapsed or refractory acute myelogenous leukemia.

                            Product Name : AUTX-703

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 24, 2025

                            Lead Product(s) : AUTX-703

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Auron Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Auron Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUTX-703

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : DCVC Bio

                            Deal Size : $27.0 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            Auron Gets FDA Nod for AUTX-703, Completes Series B Financing

                            Details : The proceeds from the raise will be used to advance AUTX-703 through a Phase 1 clinical proof-of-concept trial for the treatment of AML.

                            Product Name : AUTX-703

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 04, 2025

                            Lead Product(s) : AUTX-703

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : DCVC Bio

                            Deal Size : $27.0 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Auron Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Auron Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUTX-703

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Auron Gets FDA Nod for AUTX-703 Clinical Start & Completes Series B Financing

                            Details : AUTX-703 is a potent, selective, orally bioavailable small molecule degrader. It is being evaluated for the treatment of patients with small cell lung cancer, neuroendocrine prostate cancer..

                            Product Name : AUTX-703

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 04, 2025

                            Lead Product(s) : AUTX-703

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Auron Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Auron Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUTX-703

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Auron Selects First Development Candidate from Its AURIGIN Platform

                            Details : AUTX-703 is an orally bioavailable small molecule degrader under preclinical evaluation for treating small cell lung cancer, neuroendocrine prostate cancer, and acute myeloid leukemia.

                            Product Name : AUTX-703

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 02, 2024

                            Lead Product(s) : AUTX-703

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Auron Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed

                            Auron Therapeutics

                            U.S.A arrow
                            AMWC Asia-TDAC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : DCVC Bio

                            Deal Size : $48.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Auron Therapeutics Announces $48 Million Series A Financing to Drive Novel Oncology Pipeline Leveraging a Mach...

                            Details : Funds will also be used to expand the proprietary, machine learning-based computational platform, AURigin, that is used to identify novel drug targets, and add personnel to support and accelerate research and development.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 20, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : DCVC Bio

                            Deal Size : $48.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth